Search Back New search Go to resultsDiseaseMain groupHematological Diseases, Non-MalignantProtocol groupAnemias, CytopeniasHemolytic DiseasesDiseaseAnemia, Autoimmune Hemolytic AnemiaSubgroupCold Agglutinin Diseasewarm typeICD10D59.1MeSHAnemia, Hemolytic, AutoimmuneSequenceCADENZA : SUTI6.5, Autoimmune Hemolytic Anemia, Cold Agglutinin Disease, C1 (PID2248) -|- SUTI6.5, C2+ (PID2249)ChemotherapyChemo-substanceAzathioprineBendamustineBortezomibCiclosporin ACyclophosphamideDaratumumabFludarabineMycophenolate mofetilPrednisoloneRituximabChemo-substanceAzathioprineBendamustineBortezomibCiclosporin ACyclophosphamideDaratumumabFludarabineMycophenolate mofetilPrednisoloneRituximabChemo-substanceAzathioprineBendamustineBortezomibCiclosporin ACyclophosphamideDaratumumabFludarabineMycophenolate mofetilPrednisoloneRituximabChemo-substanceAzathioprineBendamustineBortezomibCiclosporin ACyclophosphamideDaratumumabFludarabineMycophenolate mofetilPrednisoloneRituximabNo. Substances12 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCalcium carbonateColecalciferolCotrimoxazoleDexamethasoneDimetindenEnoxaparinFolic acidFosaprepitantGranisetronMesnaMontelukastPantoprazoleParacetamolPegfilgrastimPrednisoloneSutimlimabSupportive substanceAciclovirBalanced Crystalloid SolutionCalcium carbonateColecalciferolCotrimoxazoleDexamethasoneDimetindenEnoxaparinFolic acidFosaprepitantGranisetronMesnaMontelukastPantoprazoleParacetamolPegfilgrastimPrednisoloneSutimlimabSupportive substanceAciclovirBalanced Crystalloid SolutionCalcium carbonateColecalciferolCotrimoxazoleDexamethasoneDimetindenEnoxaparinFolic acidFosaprepitantGranisetronMesnaMontelukastPantoprazoleParacetamolPegfilgrastimPrednisoloneSutimlimabSupportive substanceAciclovirBalanced Crystalloid SolutionCalcium carbonateColecalciferolCotrimoxazoleDexamethasoneDimetindenEnoxaparinFolic acidFosaprepitantGranisetronMesnaMontelukastPantoprazoleParacetamolPegfilgrastimPrednisoloneSutimlimabNo. Substances1256810Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRefractory diseaseSecond lineseveral possibleThird line Therapy phaseTherapy intentiondisease controlRisksAnemia Hb below 8g/dlArthalgiaCardiotoxicityDiarrheaDyspneaEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaHeadacheHerpes ZosterHyperbilirubinemiaHyperglycemiaHypertensionHypotensionIncrease AminotransferasesInfectionsLeukopeniaMyalgiasNasopharyngitisNeutropeniaParesthesiaPneumoniaPyrexiaRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorBerentsen SBirgens HEmilia GHoward JJalink MJäger UMichel MMoyo VMRossi GRöth ADiseaseautoimmunhämolytische Anämie, kälteagglutinin-induzierte Durchblutungsstörungenautoimmunhämolytische Anämie, Kälteagglutininerkrankungautoimmunhämolytische Anämie, KälteagglutininkrankheitAutoimmunhämolytische Anämie, Kälteagglutininkrankheit, symptomatisch, Hämoglobinwert unter 10.0 g/dL, autoimmunhämolytische Anämie, vom Wärmetyp, Drittlinieautoimmunhämolytische Anämie, vom Wärmetyp, refraktäre ErkrankungAutoimmunhämolytische Anämie, Wärmetyp und Kälteagglutininkrankheit, therapierefraktärprimäre autoimmunhämolytische Anämie, vom Wärmetypprimäre autoimmunhämolytische Anämie, vom Wärmetyp, ErstlinieOriginDepartment of Haematology, Copenhagen University Hospital, Herlev Department of Hematology, ASST Spedali Civili, Brescia, Italy, GIMEMA studyDepartment of Hematology, Leiden University Medical Center, Leiden, The NetherlandsDepartment of Medicine, Haugesund Hospital, Haugesund, NorwayDepartment of Research and Innovation, Haugesund Hospital, Hausgesund, NorwayDipartimento di Scienze Mediche, Oncologiche e Radiologiche, Università di Modena, ItalyHaugesund Hospital, Haugesund, NorwayJamaica Hospital Medical Center, Jamaica, USARoyal Free Hospital and University College Medical School, UKSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, USAUniversite Paris-Est Creteil, France, the RAIHA studyWest German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, German, CADENZA trialProtocols in Revision 14 protocols foundProtocols under revision.Azathioprine 2, Autoimmune Hemolytic Anemia, warm type (PID2008 V1.0)Bortezomib 1,3, Autoimmune Hemolytic Anemia, Cold Agglutinin Disease (PID2023 V1.0)Cyclophosphamide 50, Autoimmune Hemolytic Anemia, warm type (PID2016 V1.0)Daratumumab 1800, Autoimmune Hemolytic Anemia, Warm Type and Cold Agglutinin Disease (PID2864 V1.0)Mycophenolate Mofetil (500/1000), Autoimmune Hemolytic Anemia, warm type (PID2014 V1.0)Prednisolone (1.5/0.75/0.5) / Rituximab 375, Autoimmune Hemolytic Anemia, warm type (PID2007 V1.0)Prednisolone (1.5/0.75/0.5), Autoimmune Hemolytic Anemia, warm type (PID2006 V1.0)Prednisolone 1 / Rituximab 1000, Autoimmune Hemolytic Anemia, warm type (PID2015 V1.0)Prednisolone 5 / Ciclosporin (2.5/1.5), Autoimmune Hemolytic Anemia, warm type (PID2013 V1.0)Rituximab 375 / Bendamustine 90, Autoimmune Hemolytic Anemia / Cold Agglutinin Disease (PID1089 V1.2)Rituximab 375 / Fludarabine 25, Autoimmune Hemolytic Anemia, Cold Agglutinin Disease (PID2022 V1.0)Rituximab 375, Autoimmune Hemolytic Anemia, Cold Agglutinin Disease (PID2005 V1.0)Sutimlimab 6.5, Autoimmune Hemolytic Anemia, Cold Agglutinin Disease, Cycle 1. (PID2248 V1.0)Sutimlimab 6.5, Autoimmune Hemolytic Anemia, Cold Agglutinin Disease, Cycle 2+. (PID2249 V1.0)
